Exelixis logo
Exelixis EXEL
$ 64.59 -1.93%
report update icon

Quarterly report 2026-Q3
added 10-29-2026

Exelixis Revenue | EXEL

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Exelixis

2026 2025 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
2.32 B 2.17 B 1.83 B 1.61 B 1.43 B 968 M 968 M 854 M 452 M 37.2 M 37.2 M 25.1 M 31.3 M 47.4 M 290 M 185 M 152 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.32 B 25.1 M 789 M

Quarterly Revenue Exelixis

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
659 M 629 M 611 M 599 M 598 M 568 M 555 M 567 M 540 M 637 M 425 M 480 M 472 M 470 M 409 M 424 M 412 M 419 M 356 M 451 M 328 M 385 M 270 M 270 M 231 M 259 M 227 M 240 M 272 M 240 M 215 M 229 M 225 M 186 M 214 M 120 M 153 M 99 M 80.9 M 77.6 M 62.2 M 36.3 M 15.4 M 9.94 M 9.85 M 7.99 M 9.39 M 7.35 M 6.29 M 6.56 M 4.9 M 4.35 M 5.47 M 11.9 M 9.67 M 7.81 M 13.3 M 7.81 M 18.5 M 93.3 M 128 M 32.2 M 35.9 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
659 M 4.35 M 240 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
1.1 M $ 0.75 -9.23 % $ 4.11 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
63 M $ 7.6 -4.82 % $ 220 M usaUSA
Lipocine Lipocine
LPCN
1.98 M $ 1.47 -2.33 % $ 8.01 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
789 K $ 1.25 -6.02 % $ 11.1 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
2 M $ 3.58 -2.98 % $ 148 M israelIsrael
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
958 M $ 378.19 -4.68 % $ 8.48 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
67.8 K $ 1.2 -18.37 % $ 9.62 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
9.2 M $ 3.14 -9.13 % $ 188 M franceFrance
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
81.4 M $ 7.98 -1.97 % $ 642 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
1.5 B $ 39.21 1.76 % $ 44.9 B israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
80 M $ 60.77 -0.96 % $ 1.64 B usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
219 M $ 25.52 -2.48 % $ 2.26 B usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
52.7 M $ 2.89 -5.56 % $ 227 M israelIsrael
Foghorn Therapeutics Foghorn Therapeutics
FHTX
30.9 M $ 1.71 -3.93 % $ 108 M usaUSA
Ocugen Ocugen
OCGN
4.41 M $ 0.77 4.74 % $ 241 M usaUSA
Minerva Neurosciences Minerva Neurosciences
NERV
41.2 M $ 2.03 -4.25 % $ 17.2 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
2.86 B $ 150.5 -3.89 % $ 15 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
32.6 M $ 26.12 -1.7 % $ 1.25 T franceFrance
Prothena Corporation plc Prothena Corporation plc
PRTA
9.68 M $ 8.12 -3.33 % $ 437 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
36.5 M $ 0.26 -5.45 % $ 207 M britainBritain
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
186 M $ 6.99 -2.85 % $ 1.01 B usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
49.8 M $ 1.53 -8.68 % $ 555 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
4.58 T $ 21.79 1.66 % $ 34.4 B japanJapan
Nurix Therapeutics Nurix Therapeutics
NRIX
84 M $ 12.88 -5.29 % $ 1.12 B usaUSA
Nkarta Nkarta
NKTX
115 K $ 1.14 1.34 % $ 84.3 M usaUSA
MacroGenics MacroGenics
MGNX
150 M $ 1.97 -0.76 % $ 124 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
46 M $ 121.72 -2.2 % $ 7.74 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
309 B $ 37.8 -2.82 % $ 168 B danmarkDanmark
Marker Therapeutics Marker Therapeutics
MRKR
3.55 M $ 1.1 -17.05 % $ 16.8 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
247 M $ 15.62 -1.01 % $ 1.68 B usaUSA
NextCure NextCure
NXTC
22.4 M $ 6.62 -2.43 % $ 35.2 M usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
3.18 B $ 553.08 -1.08 % $ 24.5 B usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
39.2 M $ 115.19 -3.52 % $ 9.73 B usaUSA
Oragenics Oragenics
OGEN
37.7 K $ 0.16 -6.16 % $ 345 K usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
7.25 M $ 2.2 -5.98 % $ 286 M usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
15.4 M $ 16.11 1.26 % $ 2.76 B usaUSA
Precigen Precigen
PGEN
9.68 M $ 4.21 1.08 % $ 1.32 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
18.8 M $ 6.94 -0.57 % $ 956 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
4.36 K $ 0.66 -7.55 % $ 3.95 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
8.55 M $ 300.01 -3.5 % $ 6.75 B usaUSA